Crossmark

Development and optimization of multivesicular gefitinib liposomal transdermal system employing lipoid S100 for breast cancer: pharmacokinetics, bioavailability, and skin irritation studies in Wistar rats

Crossref DOI link: https://doi.org/10.1186/s43094-024-00729-8

Published Online: 2024-11-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patel, Jyoti S.

Raghavendra, Nulgumnalli Manjunathaiah

Sajeev Kumar, B. https://orcid.org/0000-0001-8882-5856
License Information

Text and Data Mining valid from 2024-11-14

Version of Record valid from 2024-11-14
More Information

Article History

Received: 2 July 2024

Accepted: 24 October 2024

First Online: 14 November 2024

Declarations

:

: The protocol was approved by CPCSEA, New Delhi (Reg: 606/PO/Re/S2002/CPCSEA). The study was performed in agreement with the Registration No. DSU/M.Pharm/IAREC/104/2022-23/CPCSEA).

: Not Applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below